TMS denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits TMS Sessions — and Why You Can Appeal

Transcranial Magnetic Stimulation (TMS) is a non-invasive brain-stimulation therapy used for treatment-resistant depression and certain other psychiatric conditions. UnitedHealthcare approves TMS under specific coverage policies but routinely caps the number of sessions permitted in a treatment course or a calendar year. A quantity-limits denial means the plan has approved TMS in principle but has determined your requested session count exceeds its defined ceiling.

This type of denial is highly appealable. Quantity limits are set by the insurer's internal utilization-management criteria, not by clinical outcome data from your individual case. When your treating psychiatrist or neurologist documents that additional sessions are medically necessary for your specific situation — because your response has been partial, because your condition has relapsed, or because your clinical picture deviates from a simple first-course scenario — the insurer is obligated to evaluate that individualized evidence.

## Federal Appeal Rights

You have layered federal protections:

• Internal appeal (Level 1): Required before external review. Submit within the timeframe shown on your denial notice (typically 180 days). The plan must decide within 30 days for ongoing care or 72 hours for urgent/expedited requests.
• External independent review (ACA §2719): After exhausting internal appeals, you may request external review by an independent review organization (IRO). For non-urgent cases the window is generally within four months of the final internal denial. The IRO's decision binds the insurer.
• ERISA §503 (employer-sponsored plans): Guarantees a full-and-fair review of your claim with access to the complete file used in the decision.
• Expedited review: If delaying treatment would seriously jeopardize your health or your ability to regain maximum function, request simultaneous internal and external expedited review.

## What to Gather

• Diagnosis documentation: DSM-based diagnosis from your treating clinician confirming the condition TMS was prescribed for.
• Prior treatment history: Dated records showing every antidepressant or other treatment tried, doses escalated, duration, and documented reason for discontinuation or inadequate response.
• Clinical severity: Chart notes, validated symptom-rating scales, and functional-impairment documentation showing your current severity and trajectory.
• Session-response record: Progress notes from every TMS session already completed, demonstrating partial or ongoing clinical response that supports continuation.
• Prescriber medical-necessity letter: A letter from your TMS provider explaining — in terms that map directly to UHC's published coverage criteria — why the quantity you need is medically necessary for your case.

## Criteria-Mapping Structure

Obtain two documents: (1) the FDA clearance summary for the specific TMS device being used, and (2) UnitedHealthcare's current published Coverage Determination Guideline for TMS. List every criterion the policy requires. For each criterion, write the precise chart fact that satisfies it. Where the policy cites a session limit, provide your clinician's documented rationale for why that limit is insufficient for your case. This one-to-one mapping is the core of a successful quantity-limits appeal.